Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

bluebird bio Inc (BLUE), Nektar Therapeutics (NKTR) Among Billionaire Stan Druckenmiller’s Top Small-Cap Picks

Page 1 of 2

Stan Druckenmiller’s Duquesne Family Office LLC, previously Duquesne Capital, has filed its 13F for the reporting period of March 31. Druckenmiller founded Duquesne Capital in 1981 but closed the fund to outside investors in 2010 after not being able to deliver higher returns to his clients. The investment manager had nearly $12 billion in assets at the time of closing his fund. Duquesne Family Office LLC’s public equity portfolio stands at $786.99 million as of the reporting period, with Illumina, Inc. (NASDAQ:ILMN) and Biogen Inc (NASDAQ:BIIB) holding down the top two spots in the portfolio. Druckenmiller has positions in numerous small-cap stocks, which we will discuss in this article, with the leaders being bluebird bio Inc (NASDAQ:BLUE), Nektar Therapeutics (NASDAQ:NKTR), Banco Macro SA (ADR) (NYSE:BMA), and Mattress Firm Holding Corp (NASDAQ:MFRM).


Most investors can’t outperform the stock market by individually picking stocks because stock returns aren’t evenly distributed. A randomly picked stock has only a 35% to 45% chance (depending on the investment horizon) to outperform the market. There are a few exceptions, one of which is when it comes to purchases made by corporate insiders. Academic research has shown that certain insider purchases historically outperformed the market by an average of seven percentage points per year. This effect is more pronounced in small-cap stocks. Another exception is the small-cap stock picks of hedge funds. Our research has shown that the 15 most popular small-cap stocks among hedge funds outperformed the market by nearly a percentage point per month between 1999 and 2012. We have been forward testing the performance of these stock picks since the end of August 2012 and they have returned more than 144% over the ensuing 32 months, outperforming the S&P 500 Index by nearly 85 percentage points (read the details here). The trick is focusing only on the best small-cap stock picks of funds, not their large-cap stock picks which are extensively covered by analysts and followed by almost everybody.

With 184,082 shares valued at $22.23 million, bluebird bio Inc (NASDAQ:BLUE) is the largest small-cap stock holding of Druckenmiller. The shares of the biotechnology company have been on a tear in 2015, more than doubling, with year-to-date returns of 109.42%. In fact it’s appreciated so much in the last few days that it’s no longer technically a small-cap stock, though it was as of March 31. The company’s shares picked up after it reported that it would announce clinical results for the current ongoing phase study of LentiGlobin on June 13, 2015. A brief abstract presented by the company did give positive hints about the effect of LentiGlobin in sickle cell disease and beta-thalassemia. Israel Englander‘s Millennium Management and James Flynn’s Deerfield Management hold large positions in bluebird bio Inc (NASDAQ:BLUE).

Nektar Therapeutics (NASDAQ:NKTR) is the second-largest small-cap pick of Duquesne Capital with the fund owning 655,000 shares valued at $7.21 million. The biopharmaceutical company has a market cap of $1.50 billion and its shares trade at a current P/E ratio of 66.60. However, the shares of the biotechnology firm have declined 24.8% in the current year. The clinical-stage biopharmaceutical company reported extraordinary revenue growth in the first quarter of 2015, coinciding with the sale of Movantik in the U.S for the first time. Nektar Therapeutics (NASDAQ:NKTR) reported quarterly revenue of $108.8 million against a revenue of $19.8 million in the first quarter of 2014. Millennium Management and D E Shaw are among the primary investors of Nektar Therapeutics (NASDAQ:NKTR).

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!